Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. - Ellis,M.J.; Coop,A.; Singh,B.; Mauriac,L.; Llombert-Cussac,A.; Janicke,F.; Miller,W.R.; Evans,D.B.; Dugan,M.; Brady,C.; Quebe-Fehling,E.; Borgs,M. (J Clin Oncol, 2001)